Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
FDA-approved March 19, 2026 at 7.2 mg, with 20.7% mean weight loss — closing much of the gap to tirzepatide.
Until 2026, the honest answer to "which injectable produces more weight loss" was tirzepatide. The SURMOUNT-5 head-to-head trial found Zepbound averaged 20.2% against Wegovy's 13.7%, and that six-point gap drove a lot of prescribing decisions.
Wegovy HD narrows it considerably. The FDA approved the 7.2 mg dose on March 19, 2026 — the fourth product cleared under its National Priority Voucher program — and Novo Nordisk reports 20.7% mean weight loss, roughly 21% at 72 weeks among patients who stayed on treatment and about 19% regardless.
This is not a new molecule. It is the same semaglutide at a higher dose, aimed specifically at people who tolerated a lower dose but did not achieve sufficient weight loss on it.
Wegovy HD is semaglutide 7.2 mg injection, FDA-approved on March 19, 2026 for weight loss and long-term weight maintenance. It is indicated as an adjunct to diet and activity for additional weight loss in adults with obesity who have already tolerated a lower dose. Mean weight loss was 20.7%, and it was superior to the 2.4 mg dose with an estimated treatment difference of −3.1% at 72 weeks. It was already approved in the EU and UK at 7.2 mg.
Average weight loss figures come from each product's own pivotal trial reporting. Cross-trial comparison is imperfect, but SURMOUNT-5 was a direct head-to-head between Zepbound and Wegovy 2.4 mg.
| Medication | Dose | Average weight loss | Notes |
|---|---|---|---|
| Wegovy HD | Semaglutide 7.2 mg | 20.7% mean | Approved March 19, 2026; ~21% at 72 weeks on treatment, ~19% regardless |
| Zepbound | Tirzepatide | 20.2% (SURMOUNT-5) | Head-to-head against Wegovy 2.4 mg |
| Wegovy | Semaglutide 2.4 mg | 13.7% (SURMOUNT-5) | The standard maintenance dose |
| Foundayo | Orforglipron 17.2 mg | 11.1% | Oral, approved April 1, 2026 |
| Wegovy tablets | Oral semaglutide | Reported slightly above orforglipron | Requires empty stomach and a waiting period |
Averages do not predict individual results. Tolerability, cost and coverage often matter more than a few percentage points.
The indication is narrower than the headline suggests. Wegovy HD is indicated as an adjunct to diet and activity for additional weight loss in adults with obesity who have already tolerated a lower dose of semaglutide. It is not a starting dose.
That makes it a specific answer to a specific problem: you are on Wegovy 2.4 mg, you tolerate it fine, and your weight loss has plateaued short of your goal. Previously the main option was switching to tirzepatide and restarting titration from scratch. Now there is a route that keeps you on the same molecule.
It also matters for people who tried tirzepatide and could not tolerate it, or who are on a plan whose formulary covers Wegovy but not Zepbound. Before Wegovy HD, those patients were capped at 13.7% average weight loss. Now they are not.
It is not for anyone starting GLP-1 therapy. Every approved GLP-1 uses gradual titration precisely because gastrointestinal side effects concentrate during dose escalation, and starting high would be both ineffective and poorly tolerated.
Novo Nordisk has not published Wegovy HD-specific self-pay pricing separate from its standard Wegovy channels, so the practical answer is to use the existing routes and confirm what applies to the 7.2 mg dose.
Through NovoCare Pharmacy, Novo's direct-to-patient channel, Wegovy self-pay pricing is dose-tiered — $149 a month for the 1.5 mg and 4 mg strengths, $299 for 9 mg and 25 mg, and $399 for the injection — with free home delivery. The program originally launched at a flat $499 a month for all doses in March 2025.
For commercially insured patients, Novo runs a savings offer that can bring eligible patients to as little as $25 a month.
For Medicare beneficiaries, the GLP-1 Bridge program covers Wegovy in both injection and tablet form at $50 a month from July 1, 2026 through December 31, 2027 — by far the cheapest route if you qualify.
Moving to a higher dose restarts the pattern most people know from starting a GLP-1: nausea, vomiting, diarrhea and constipation tend to appear or worsen after an increase, then settle over the following weeks. A higher dose generally means a higher likelihood of these effects. If you are considering stepping up to Wegovy HD, plan for a rougher few weeks and make sure your prescriber will slow things down if you struggle.
Wegovy HD is a higher 7.2 mg dose of Wegovy (semaglutide) injection, approved by the FDA on March 19, 2026 for weight loss and long-term weight maintenance. It was the fourth product approved under the FDA's National Priority Voucher program and was already approved in the EU and UK at that dose.
Novo Nordisk reports 20.7% mean weight loss, with roughly 21% at 72 weeks among adults with obesity who stayed on treatment and about 19% regardless of adherence. In trial, the 7.2 mg dose was superior to 2.4 mg with an estimated treatment difference of −3.1%.
They are now very close. Wegovy HD reports 20.7% mean weight loss; Zepbound averaged 20.2% in the SURMOUNT-5 head-to-head trial against Wegovy 2.4 mg. There is no direct head-to-head between Wegovy HD and Zepbound, so cross-trial comparison should be treated cautiously.
No. Wegovy HD is indicated as an adjunct to diet and activity for additional weight loss in adults with obesity who have already tolerated a lower dose of semaglutide. All GLP-1s use gradual titration because gastrointestinal side effects concentrate during dose escalation.
Novo has not published Wegovy HD-specific self-pay pricing separate from standard Wegovy channels. Through NovoCare Pharmacy, Wegovy self-pay is dose-tiered from $149 a month for lower oral strengths up to $399 for the injection, with free home delivery. Eligible commercially insured patients may pay as little as $25 a month, and eligible Medicare beneficiaries pay $50 a month under the GLP-1 Bridge program.
A higher dose generally means a higher likelihood of gastrointestinal side effects — nausea, vomiting, diarrhea and constipation — and these concentrate during escalation before settling. Wegovy HD carries the same boxed warnings and contraindications as all semaglutide products. Read the full prescribing information and discuss with your prescriber.
The Medicare GLP-1 Bridge program covers Wegovy in both injection and tablet form at $50 a month for eligible beneficiaries from July 1, 2026 through December 31, 2027. Confirm with Medicare that your specific dose and formulation are included.
That is a clinical decision for your prescriber. It is most relevant if you tolerate your current dose well but have plateaued short of your goal. The alternative — switching to tirzepatide — means restarting titration on a different molecule, so staying on semaglutide at a higher dose may be the gentler route.
The SURMOUNT-5 head-to-head explained
Retatrutide, CagriSema and the pipeline
The oral GLP-1 approved April 2026
Full titration schedule
Wegovy at $50/month
Managing escalation
Claims on this page trace to the following sources, checked on August 30, 2026.
Explore more expert guides and reviews to help you on your weight loss journey
Complete guide explaining the difference between semaglutide, Ozempic, Wegovy, and compounded semaglutide.
Complete guide to Jardiance weight loss: how much to expect, mechanism, and comparison to GLP-1 medications.
The SURMOUNT-5 head-to-head trial: 20.2% vs 13.7% average weight loss, plus side effects and cost.
What actually differs, what the FDA changed in 2026, and how the price gap closed.
The oral GLP-1 pill approved April 1, 2026: dosing from 0.8 mg, pricing from $149/mo, and results.
Retatrutide at up to 30.3%, CagriSema at 22.7%, and realistic timelines for the GLP-1 pipeline.
This article summarizes publicly available approval and trial information about Wegovy HD and is for informational purposes only. It is not medical advice, a diagnosis, a treatment recommendation, or a substitute for the FDA-approved prescribing information. Trial averages do not predict individual results. Wegovy HD is a prescription medicine with serious potential risks including boxed warnings and is not appropriate for everyone. Never start, stop, or change a dose without your prescriber. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026